WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.   

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies. 

Disclosures for additional planners can be found here.

Moderator

Elif Arioglu Oral, MD

Professor of Internal Medicine
Division of Metabolism, Endocrinology and Diabetes
Department of Internal Medicine
University of Michigan Medical School
Ann Arbor, Michigan, United States

Disclosures

Disclosure: Elif Arioglu Oral, MD, has the following relevant financial relationships:
Consultant or advisor for: Amryt Pharma Plc; Ionis Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Third Rock Ventures
Research funding from: Amryt Pharma Plc
Contracted researcher for: Amryt Pharma Plc; Dactyl; GI Dynamics; Ionis Pharmaceuticals; Novo Nordisk; Regeneron Pharmaceuticals, Inc
Patent beneficiary of: Metreleptin owned by Amryt Pharma Plc

Faculty

David Araújo-Vilar, MD, PhD

Associate Professor and Leader
Lipodystrophies Lab UETeM
Molecular Pathology of Rare Diseases Group
Department of Psychiatry, Radiology, Public Health, Nursing and Medicine
IDIS-CiMUS
University of Santiago de Compostela
Division of Endocrinology and Nutrition
University Clinical Hospital of Santiago de Compostela
Santiago de Compostela, Spain

Disclosures

Disclosure: David Araújo-Vilar, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amryt Pharma Plc
Speaker or member of speakers bureau for: Amryt Pharma Plc
Research funding from: Aegerion Pharmaceuticals, Inc

Abhimanyu Garg, MD

Chief
Division of Nutrition and Metabolic Diseases
Department of Internal Medicine and the Center for Human Nutrition
UT Southwestern Medical Center
Dallas, Texas, United States

Disclosures

Disclosure: Abhimanyu Garg, MD, has the following relevant financial relationships:
Consultant or advisor for: Amryt Pharma Plc; Health Advances; Kyttaro Limited; Regeneron Pharmaceuticals, Inc.; Third Rock Ventures
Research funding from: Amryt Pharma Plc; Ionis Pharmaceuticals; Quintiles/Measure; Regeneron Pharmaceuticals, Inc
Stock options from: Kyttaro Limited

David Savage, MD

Professor and Wellcome Trust Senior Clinical Fellow
Metabolic Research Laboratories
Wellcome Trust-Medical Research Council Institute of Metabolic Science
University of Cambridge
Cambridge, United Kingdom

Disclosures

Disclosure: David Savage, MD, has no relevant financial relationships.

Editor

Rita Moreira Da Silva, PhD, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Rita Moreira Da Silva, PhD, PharmD, has no relevant financial relationships.

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Susan L. Smith, MN, PhD, has no relevant financial relationships.

CPD

Identify and Act: Lipodystrophy for Nonspecialists

Authors: Elif Arioglu Oral, MD; David Araújo-Vilar, MD, PhD; Abhimanyu Garg, MD; David Savage, MD
CPD Released: 5/24/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 5/24/2023

Start Activity

Target Audience and Goal Statement

This educational activity is intended for diabetologists & endocrinologists, pediatricians, and internal medicine specialists.

The goal of this activity is that learners will be better able to recognize, diagnose, and refer patients with LD syndromes to specialist centers for management and follow-up.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Burden of LD
- The importance of referring patients as early as possible to specialist centers
Have greater competence related to
- Diagnosing LD

Disclosures

Disclosures for additional planners can be found here.

Moderator

Elif Arioglu Oral, MD

Professor of Internal Medicine
Division of Metabolism, Endocrinology and Diabetes
Department of Internal Medicine
University of Michigan Medical School
Ann Arbor, Michigan, United States

Disclosures

Disclosure: Elif Arioglu Oral, MD, has the following relevant financial relationships:
Consultant or advisor for: Amryt Pharma Plc; Ionis Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Third Rock Ventures
Research funding from: Amryt Pharma Plc
Contracted researcher for: Amryt Pharma Plc; Dactyl; GI Dynamics; Ionis Pharmaceuticals; Novo Nordisk; Regeneron Pharmaceuticals, Inc
Patent beneficiary of: Metreleptin owned by Amryt Pharma Plc

Faculty

David Araújo-Vilar, MD, PhD

Associate Professor and Leader
Lipodystrophies Lab UETeM
Molecular Pathology of Rare Diseases Group
Department of Psychiatry, Radiology, Public Health, Nursing and Medicine
IDIS-CiMUS
University of Santiago de Compostela
Division of Endocrinology and Nutrition
University Clinical Hospital of Santiago de Compostela
Santiago de Compostela, Spain

Disclosures

Disclosure: David Araújo-Vilar, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amryt Pharma Plc
Speaker or member of speakers bureau for: Amryt Pharma Plc
Research funding from: Aegerion Pharmaceuticals, Inc

Abhimanyu Garg, MD

Chief
Division of Nutrition and Metabolic Diseases
Department of Internal Medicine and the Center for Human Nutrition
UT Southwestern Medical Center
Dallas, Texas, United States

Disclosures

Disclosure: Abhimanyu Garg, MD, has the following relevant financial relationships:
Consultant or advisor for: Amryt Pharma Plc; Health Advances; Kyttaro Limited; Regeneron Pharmaceuticals, Inc.; Third Rock Ventures
Research funding from: Amryt Pharma Plc; Ionis Pharmaceuticals; Quintiles/Measure; Regeneron Pharmaceuticals, Inc
Stock options from: Kyttaro Limited

David Savage, MD

Professor and Wellcome Trust Senior Clinical Fellow
Metabolic Research Laboratories
Wellcome Trust-Medical Research Council Institute of Metabolic Science
University of Cambridge
Cambridge, United Kingdom

Disclosures

Disclosure: David Savage, MD, has no relevant financial relationships.

Editor

Rita Moreira Da Silva, PhD, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Rita Moreira Da Silva, PhD, PharmD, has no relevant financial relationships.

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Susan L. Smith, MN, PhD, has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Identify and Act: Lipodystrophy for Nonspecialists

Authors: Elif Arioglu Oral, MD; David Araújo-Vilar, MD, PhD; Abhimanyu Garg, MD; David Savage, MD Faculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 5/24/2022

Valid for credit through: 5/24/2023

processing....

Contents of This CPD Activity

Clinician Handout

All sections of this activity are required for credit.

What Is Lipodystrophy, the Natural History, and Burden of This Disease?   

Learn more about the epidemiology and pathophysiology of this rare condition.
Elif Arioglu Oral, MD

Diagnosing Lipodystrophy: Overcoming the Challenges

How prepared are you to identify and diagnose lipodystrophy (LD) syndromes?
Elif Arioglu Oral, MD

A Case Review of Recognition and Diagnosis

Go from theory to practice with a walk-through description of a real patient with LD.
Abhimanyu Garg, MD

Management of Lipodystrophy: The Role of Leptin Replacement Therapy

As an important hormone in the pathophysiology of LD, learn here how leptin determines its management.
David Araújo-Vilar, MD, PhD

Act by Referring to Specialist Centers

Timely referral is key to optimize management of patients with LD: the experience of the United Kingdom.
David Savage, MD

Page 1 of 6

What Is Lipodystrophy

CPD Information Download Slides

Activity Transcript

PDF Downloads

Clinician Handout

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Faculty and Disclosures

Moderator

Elif Arioglu Oral, MD

Faculty

David Araújo-Vilar, MD, PhD

Abhimanyu Garg, MD

David Savage, MD

Editor

Rita Moreira Da Silva, PhD, PharmD

Compliance Reviewer

Susan L. Smith, MN, PhD

CPD

Identify and Act: Lipodystrophy for Nonspecialists

Target Audience and Goal Statement

Disclosures

Moderator

Elif Arioglu Oral, MD

Faculty

David Araújo-Vilar, MD, PhD

Abhimanyu Garg, MD

David Savage, MD

Editor

Rita Moreira Da Silva, PhD, PharmD

Compliance Reviewer

Susan L. Smith, MN, PhD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Identify and Act: Lipodystrophy for Nonspecialists

Contents of This CPD Activity

Clinician Handout

What Is Lipodystrophy, the Natural History, and Burden of This Disease?

Diagnosing Lipodystrophy: Overcoming the Challenges

A Case Review of Recognition and Diagnosis

Management of Lipodystrophy: The Role of Leptin Replacement Therapy

Act by Referring to Specialist Centers

PDF Downloads

What Is Lipodystrophy, the Natural History, and Burden of This Disease?   